Convegno Interregionale SIE

Delegazione Triveneto

NUOVE TERAPIE NEI LINFOMI B AGGRESSIVI E NEL MIELOMA MULTIPLO

CRO Aviano (PN) 9 ottobre 2024



CAR-T nella terapia di salvataggio del Mieloma Multiplo F. Patriarca (Udine)




Disclosures of Francesca Patriarca

Company name	Research support	Employee	Consultant	Stockholder	Speakers bureau	Advisory board	Other
BMS						Х	
Menarini					Х		
Sanofi					х	Х	
Novartis					х	Х	

OUTLINE


- Registrative studies and real life of ide-cel and cilta-cel
- MM specific scores
- Randomized studies
- Studies in early MM


Potential Therapeutic Targets of CAR-T cells in MM



Zhang X et al, Front Immunology 2023

Second-generation CAR-T targeting BCMA





Cilta cel



BCMA-directed CAR-T cell product for multiple myeloma

	Ide-cabtagene vicleucel (ide-cel)	Ciltacabtagene autocel (cilta-cel)
Construct	Anti-BCMA-41BB-CD3z	Anti-BCMA2-41BB-CD3z
FDA approval status	 Adults with relapsed/refractory MM after at least 4 prior therapies, including an immunomodulating agent, a protesome inhibitor and a antiCD38-monoclonal antibody (26/3/21) 	 Adults with relapsed/refractory MM after at least 4 prior therapies, including an immunomodulating agent, a protesome inhibitor and a antiCD38-monoclonal antibody (14/2/22)
EMA approval	 Adults with relapsed/refractory MM after at least 3 prior therapies, including an immunomodulating agent, a protesome inhibitor and a antiCD38-monoclonal antibody Conditional approval 20/8/21 	 Adults with relapsed/refractory MM after at least 3 prior therapies, including an immunomodulating agent, a protesome inhibitor and a antiCD38-monoclonal antibody Conditional approval 26/5/22
AIFA approval status	• May 2024	• Pending

Clinical patients features in registrative studies

	lde-cel	Cilta-cel
Author	Munshi et al, NEJM 2021	Berdeja et al, Lancet 2021 Martin et al, JCO 2023
Study phase	II	lb/II
N° pts	128	97
N° previous lines	6 (3-16)	6 (3-18)
Triple class refractory	84%	88%
High risk cytogenetics	35%	24%
EMD	39%	13%
Median follow-up (months)	13	33 (1-45)

Munshi et al, NEJM 2021

Efficacy in registrative studies

	Ide-cel	Cilta-cel
Author	Munshi et al, NEJM 2021	Berdeja et al, Lancet 2021 Martin et al, JCO 2023
N° pts	128	97
OR%	73	98
CR%	33	82
Median DOR (months)	10.2	NR
Median PFS (months)	8.8	34.9

Munshi et al, NEJM 2021

ANTI-BCMA CAR-T ADVERSE EFFECTS

	lde-cel	Cilta-cel
Study name	KarMMa	Cartitude-1
N° pts	128	97
CRS All grades <u>></u> Grade 3 Grade 5 Median onset (range)	107 (84%) 7 (6%) 1 (> 1%) 1 (1-12)	92 (95%) 5 (4%) 1 (<1%) 7 (5-8)
Neurotoxicities all grades Grade 3-4 Grade 5	ICANS 23 (18%) 4(3%) 4 (3%)	ICANS%parkinsonism%cranial nerve palsy 21 (21%) 11(12%) 1 (1%)
Hematological tx Neutropenia all grades Neutropenia grade 3-4 Thrombocytopenia all grades Thrombocytopenia grade 3-4	117 (91%) 114 (89%) 81 (63%) 67 (52%)	93 (96%) 92 (95%) 77 (79%) 58 (60%)
Infections all grades % Infections grade 3-4 %	69% 22%	58% 20%

LATE ADVERSE EVENTS

	lde-cel	Cilta-cel
Study name	KarMMa	Cartitude-1
N° pts	128	97
Severe adverse events	9 (7%)	6 (6%)
< 2 months	3 (CRS, lung aspergillosis, gastrointestinal hemorraghe)	2 (CRS, sepsis)
2-6 months	1 (CMV pneumonia)	3 (sepsis, lung ascess, respiratory failure)
6-24 months	5 7% SPM 1% myeloid neoplams	 1 (neurotoxicity) 21% SPM 9% myeloid neoplasm 1% T-lymphoma

USA real-word experience with ide-cel


196 pts leukaphered

159 pts (81%) infused

120 pts (75%) ineligible in karMMA study due to comorbidities, organ failures, prior antiBCMA, MM complications

Similar efficacy and toxicity

Pts with previous exposure to BCMA– targeted therapy, high-risk cytogenetics, ECOG PS > 2 at lymphodepletion, and younger age had inferior PFS on multivariable analysis



Hansen D et al, JCO 2022

Outcomes in older vs. younger patients

	≥70 years (N=251), N (%)	<70 years (N=570), N (%)	Р
Overall response	192 (76.5)	400 (70.2)	0.05
CR or better	68 (27.1)	136 (23.9)	0.29
Relapse at 6 months, %, (95% CI)	26.6 (21.0–32.7)	36.9 (32.8–41.1)	<mark><0.01</mark>
TRM at 6 months, %, (95% CI)	5.1 (2.6–8.5)	2.7 (1.5–4.2)	0.07
PFS at 6 months, %, (95% CI)	68.3 (61.9–74.3)	60.4 (56.2–64.6)	<mark>0.03</mark>
OS at 6 months, %, (95% CI)	85.5 (80.5–89.9)	82.6 (79.2–85.7)	0.18
CRS any grade	197 (78.5)	460 (80.7)	0.46
CRS, grade ≥3	8 (3.2)	16 (2.8)	0.87
NT, any grade	93 (37.1)	138 (24.2)	<mark><0.01</mark>
NT, grade ≥3	14 (5.6)	25 (4.4)	0.69

A p-value of <0.05 was considered statistically significant.

CR, complete response; CRS, cytokine-release syndrome; NT, neurotoxicity; OS. overall survival; PFS. progression-free survival; TRM, treatment-related mortality.

Characteristics and outcomes of frail patients receiving ide-cel


Characteristic	Frail (N=343) N (%)	Non-frail (N=423) N (%)	Р
Median age, years (range)	67.1 (29.3–85.9)	64.4 (35.0–79.7)	<0.01
ECOG PS ≥2	<mark>42 (12.2)</mark>	<mark>0 (0.0)</mark>	<mark><0.01</mark>
Clinically significant comorbidity	<mark>334 (97.4)</mark>	<mark>253 (59.8)</mark>	<mark><0.01</mark>
Extramedullary disease	28 (8.2)	50 (11.8)	<0.01
Relapse at 6 months, %, (95% CI)	33.9 (28.7–39.3)	33.8 (29.1–38.7)	0.65
TRM at 6 months, %, (95% CI)	5.3 (3.0–8.1)	1.9 (0.7–3.5)	0.40
PFS at 6 months, %, (95% CI)	60.9 (55.3–66.3)	64.3 (59.4–69.1)	0.35
OS at 6 months, %, (95% CI)	79.5 (74.8–83.8)	85.6 (81.9–88.9)	0.08
CRS, grade ≥3	14 (4.1)	9 (2.1)	0.06
NT, grade ≥3	21 (6.1)	17 (4.0)	0.41
Clinically significant infections	<mark>170 (49.6)</mark>	<mark>173 (40.9)</mark>	<mark>0.02</mark>
Prolonged cytopenia	67 (26.7)	161 (28.2)	0.01

CRS, cytokine-release syndrome; ECOG, Eastern Cooperative Oncology Group; ide-cel, idecabtagene vicleucel; NT, neurotoxicity; OS, overall survival; PFS, progression-free survival; PS, performance status; TRM, treatment-related mortality.


SCORE HEMATOX AND OUTCOME

Retrospective study on 113 r/r multiple myeloma patients treated mainly with ide-cel across six international CAR-T centers.

One point was allotted for the following criteria: ANC \leq 1200/µl, hemoglobin \leq 9.0 g/dl, platelet count 76–175 G/l, CRP \geq 3.0 mg/dl, and ferritin 650–2000 ng/ ml. Two points were provided for a platelet count \leq 75 G/l and ferritin \geq 2000 ng/ml. A sum score of 2 or greater was classified as high risk (HThigh), a score of 0–1 as low risk (HTlow).UHThigh >5



SCORE HEMATOX AND OUTCOME



Rejeski K et al, J Hematology & Oncology 2023

Myeloma CAR-T Relapse [MyCARe] model

International retrospective observational study including patients with RRMM infused with currently available commercial or academically produced anti–B-cell maturation antigen (BCMA) CAR-T in Europe (136) and the United States (133).






TABLE 2. Multivariable Modeling of Early Relapse/Progression

Factor	HR	95% CI	Р	Score
EMD or PCL present	1.92	1.30 to 2.82	<.001	1
High-risk cytogenetics	1.95	1.31 to 2.92	.001	1
Ferritin > NL (sex-/age-adjusted)	1.59	1.07 to 2.37	.02	1
Lenalidomide refractoriness	1.69	1.02 to 2.82	.04	1
MyCARe risk				
Low (score 0-1)	Ref			7.9
Intermediate (score 2-3)	3.27	1.87 to 5.72	<.001	
High (score 4)	7.89	4.21 to 14.79	<.001	

Myeloma CAR-T Relapse [MyCARe] model



KarMMa-3 study design



^aTime from randomization to the first occurrence of disease progression or death from any cause according to IMWG criteria.

^bUp to 1 cycle of DPd, DVd, IRd, Kd, or EPd may be given as bridging therapy with a minimum of 14 days of washout.


CAR, chimeric antigen receptor; CRR, complete response rate; DOR, duration of response; DPd, daratumumab/pomalidomide/dexamethasone; DVd, daratumumab/bortezomib/dexamethasone; EPd, elotuzumab/pomalidomide/dexamethasone; ide-cel, idecabtagene vicleucel; IMiD, immunomodulatory agent; IMWG, International Myeloma Working Group; IRC, independent review committee; IRd, ixazomib/lenalidomide/dexamethasone; Kd, carfilzomib/dexamethasoneLDC, lymphodepleting chemotherapy; MRD, minimal residual disease; ORR, overall response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PI, proteosome inhibitor: PK_pharmacokinetics: OOL_culatity of life: R_randomization; TTR, time to resolution.

Rodriguez-Oter et al, NEJM 2023

Ide-cel or standard treatments in RR MM after 2-4 prior regimens

	lde-cel	Standard therapy
N° pts	254	132
High risk cytogenetics	42%	46%
Extramedullary MM	24%	24%
N° previous lines	3(2-4)	3 (2-4)
Triple class refractory	65%	67%
Penta drug refractory	6%	4%


Rodriguez-Oter et al, NEJM 2023



Rodriguez-Oter et al, NEJM 2023

KarMMa-2

KarMMa-2 cohort 2 study design




^aAfter lymphodepletion (cyclophosphamide 300 mg/m² + fludarabine 30 mg/m² × 3), patients received a single infusion of ide-cel at a range of $150-450 \times 10^6$ CAR+ T cells (up to an additional 20%; 20% over the protocol-specified dose constituted overdose); ^bAt investigator discretion, patients could receive maintenance treatment post-infusion; ^cMeasurable disease determined by M protein (serum protein electrophoresis ≥ 0.5 g/dL or urine protein electrophoresis ≥ 200 mg/24 hours) and/or light chain MM without measurable disease in serum or urine (serum immunoglobulin free light chain ≥ 10 mg/dL and abnormal serum immunoglobulin $\kappa:\lambda$ free light chain ratio); ^dMust contain a PI, an IMiD[®] agent, and dexamethasone.

ASCT, autologous stem cell transplantation; CAR, chimeric antigen receptor; CR, complete response; CRR, complete response rate; DOR, duration of response; ECOG, Eastern Cooperative Oncology Group; HRQoL, health-related quality of life; ide-cel, idecabtagene vicleucel; IMiD, immunomodulatory drug; IMWG, International Myeloma Working Group; MM, multiple myeloma; MRD, minimal residual disease; ORR, overall response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PI, proteasome inhibitor; PK, pharmacokinetics; sCR, stringent complete response; TTP, time to progression; TTR, time to response; VGPR, very good partial response.

Madhav Dhodapka, abstract 2101

Best overall response



Overall (N = 31)

Lenalidomide maintenance (n = 8)


36-month PFS rate of 76.8%

Madhav Dhodapka, abstract 2101

KarMMa-2



MRD negativity




CR, complete response; ide-cel, idecabtagene vicleucel; MRD, minimal residual disease.

Madhav Dhodapka, abstract 2101

CARTITUDE-4: Study Design and Endpoints

Median follow-up was 15,4 months



Primary endpoint

PFS^c

Secondary endpoints

- Efficacy: ≥CR, ORR, MRD negativity, OS
- Safety
- PROs

Einsele H et al, EHA2023 San Miguel et al, NEJM 2023

*Physicians' choice. *Administered until disease progression. *Time from randomization to disease progression/death.

BCMA, B-cell maturation antigen: CAR, chimeric antigen receptor; cilta-cel, ciltacabtagene autoleucel; CR, complete response; DPd, daratumumab, pomalidomide, and dexamethasone; ECOG PS, Eastern Cooperative Oncology Group performance status; IMiD, immunomodulatory drug; ISS, International Staging System; Ien, Ienalidomide; LOT, line of therapy; MM, multiple myeloma; MRD, minimal residual disease; ORR, overall response rate; OS, overall survival; PD, pharmacodynamics; PFS, progression-free survival; PI, proteasome inhibitor; PK, pharmacokinetics; PRO, patient-reported outcome; PVd, pomalidomide, bortezomib, and dexamethasone; SOC, standard of care.


CARTITUDE-4: Baseline Demographics and Disease Characteristics

	ITT population		
Baseline characteristic	Cilta-cel (n=208)	SOC (n=211)	
Age, median (range), years	61.5 (27–78)	61.0 (35-80)	
Male, n (%)	116 (55.8)	124 (58.8)	
White, n (%)	157 (75.5)	157 (74.4)	
ECOG PS ≤1, n (%) ^{ab}	207 (99.5)	210 (99.5)	
ISS stage, n (%)			
1	136 (65.4)	132 (62.6)	
	60 (28.8)	65 (30.8)	
III	12 (5.8)	14 (6.6)	
Bone marrow plasma cells ≥60%, ^c n (%)	42 (20.4)	43 (20.7)	
Presence of soft tissue plasmacytomas, ^d n (%)	44 (21.2)	35 (16.6)	
Years since diagnosis, median (range)	3 (0.3–18.1)	3.4 (0.4–22.1)	
Prior LOT, median (range)	2 (1-3)	2 (1-3)	
1 prior LOT, n (%)	68 (32.7)	68 (32.2)	
2 or 3 prior LOT, n (%)	140 (67.3)	143 (67.8)	

	ITT po	pulation
Baseline characteristic	Cilta-cel (n=208)	SOC (n=211)
Cytogenetic high risk, n (%) ^e	123 (59.4)	132 (62.9)
del(17p)	49 (23.7)	43 (20.5)
t(14;16)	3 (1.4)	7 (3.3)
t(4;14)	30 (14.5)	30 (14.3)
gain/amp(1q)	89 (43.0)	107 (51.0)
2 or more high-risk cytogenetic features	43 (20.8)	49 (23.3)
del(17p), t(14;16), or t(4;14)	73 (35.3)	69 (32.9)
Triple-class ^r exposed, n (%)	53 (25.5)	55 (26.1)
Penta-drug ⁹ exposed, n (%)	14 (6.7)	10 (4.7)
Refractory status, n (%)		
Triple-class refractory ⁽⁾	30 (14.4)	33 (15.6)
Bortezomib	55 (26.4)	48 (22.7)
Pomalidomide	8 (3.8)	9 (4.3)
Daratumumab	48 (23.1)	45 (21.3)
Any PI	103 (49.5)	96 (45.5)

*1 patient in each arm had ECOG PS of 2. ^bLatest nonmissing ECOG PS score on or prior to apheresis/cycle 1 day 1 is used. ⁹In 206 (cilta-cel arm) and 208 (SOC arm) patients, maximum value from bone marrow biopsy and bone marrow aspirate is selected if both results are available. ⁹Including extramedullary and bone-based plasmacytomas with measurable soft tissue component. ¹In 207 (cilta-cel arm) and 210 (SOC arm) patients. Including 1 PI, 1 IMID, and 1 anti-CD38 monoclonal antibody. ⁹Including ≥ 2 PI, ≥2 IMIDs, and 1 anti-CD38 monoclonal antibody. ¹Co arm) were penta-drug refractory, including ≥ 2 PI, ≥2 IMIDs, and 1 anti-CD38 monoclonal antibody. ¹Co arm) were penta-drug refractory, including settern: IT, intent-to-treat; LOT, line of therapy; PI, proteasome inhibitor; SOC, standard of care.

CARTITUDE-4: Primary Endpoint – PFS (ITT Population)



*Median follow-up, 15.9 months. *Constant piecewise weighted log-rank test. HR and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable, including only PFS events that occurred >8 weeks post randomization.


cilta-cel, ciltacabtagene autoleucel; HR, hazard ratio; ITT, intent-to-treat; mPFS, median progression-free survival; NE, not estimable; SOC, standard of care.

Median follow-up was 15,4 months

Einsele H et al, EHA2023, San Miguel J et al NEJM 2023


7

Long-Term CARTITUDE-4 Update (34 Months): Cilta-cel Maintained Significant Improvement in Progression-Free Survival



~70% reduction in the risk of progression or death in patients who received cilta-cel and mPFS has not been reached

Long-Term CARTITUDE-4 Update (34 Months): Cilta-cel Significantly Improved Overall Survival



First CAR-T to demonstrate overall survival benefit in multiple myeloma

Â


Long-Term CARTITUDE-4 Update (34 Months): Consistent Progression-Free Survival Benefit for Cilta-cel Across All Prespecified Subgroups

	←Favor cilta-cel arm Fa	avor SOC arm $\rightarrow \frac{HR^a}{(95\% CI)}$		← Favor cilta-cel arm Favor SOC arm → $\frac{HR^a}{(95\% \text{ Cl})}$	
Number of lines of prior therapy			Cytogenetic risk at study entry		. ,
1	⊢ •–-1	0.41 (0.25–0.67)	High risk ^d Any of 4 markers abnormal	⊢ •	0.29 (0.20-0.41)
2 or 3	⊢ ⊷⊣	0.26 (0.18–0.37)	At least 2 of 4 markers abnormal		0.30 (0.17–0.54)
ISS staging ^b			Excl. gain/amp(1q)		0.26 (0.16–0.42)
I	⊢ ⊷⊣	0.28 (0.19–0.41)	Standard risk	⊢ •−•	0.32 (0.18–0.59)
II	⊢ •−-1	0.31 (0.18–0.51)	Refractory to		
III	⊢ • †	0.41 (0.16–1.09)	PI + IMiD Anti-CD38 + IMiD		0.25 (0.17–0.38) 0.25 (0.14–0.44)
Presence of soft tissue			PI + anti-CD38 + IMiD	→→→	0.17 (0.08–0.38)
plasmacytomas			Last line of prior therapy	⊢ •	0.30 (0.22–0.40)
Yes	⊢ •−	0.36 (0.20-0.66)	Prior exposure to		
No		0.28 (0.20-0.39)	Daratumumab	⊢ •i	0.24 (0.14–0.42)
Townshield			Bortezomib	⊢ •	0.30 (0.22–0.40)
Tumor burden ^c			Bortezomib and daratumumab	⊢_ •	0.24 (0.13-0.43)
Low	⊢ •−1	0.27 (0.18–0.41)	Daratumumab naive		
Intermediate	⊢ ⊷i	0.34 (0.19–0.60)	Yes		0.31 (0.22–0.44)
High	⊢ •−	0.21 (0.10–0.44)	No	⊢ •−i	0.24 (0.14–0.42)
			—		

Consistent reduction in the risk of progression or death across all prespecified subgroups

Â

Long-Term CARTITUDE-4 Update (34 Months): Increased Rates of Deep Responses Seen With Additional Follow-Up With Cilta-cel



ORR^a


DOR^b

	Cilta-cel	SOC
DOR, months, median (95% CI)	NR (NE–NE)	18.7 (12.9–23.7)
30-month DOR rate, % (95% CI)	67.4 (59.7–74.0)	35.5 (27.6–43.6)

Cilta-cel provided high ORR and sCR/CR rate with sustained DOR

Â


Long-Term CARTITUDE-4 Update (34 Months): Cilta-cel Provided Significantly Higher Rate of MRD Negativity



Cilta-cel increased MRD negativity more than 2-fold at 10⁻⁵, and more than 4-fold at 10⁻⁶ vs SOC

 $\widehat{}$

CARTITUDE-4 Subgroup Analysis: Patient Population




Functionally high-risk MM defined as PD ≤18 months after receiving ASCT or the start of initial frontline therapy in patients with no ASCT

At the November 2022, data cut-off date, median follow-up was 15.9 months (range, 0.1–27.3). Among 68 patients who received 1 prior LOT in the cilta-cel arm, 60 received cilta-cel as study treatment, 5 received cilta-cel as subsequent therapy, and 3 never received cilta-cel. Among 40 patients who received 1 prior LOT and functionally high-risk MM in the cilta-cel arm, 35 received cilta-cel as study treatment includes any portion of the following sequence: apheresis, bridging, lymphodepletion, and cilta-cel.

ASCT, autologous stem cell transplant; cilta-cel, ciltacabtagene autoleucel; LOT, line of therapy; MM, multiple myeloma; PD, progressive disease; SOC, standard of care.

í 🗋

CARTITUDE-4 Subgroup Analysis: Consistently Deeper Responses Achieved With Cilta-cel vs SOC in Patients With 1 Prior LOT and Those With 1 Prior LOT and Functionally High-Risk MM



Treatment response was assessed by a validated computerized algorithm, based on International Myeloma Working Group consensus criteria. ORR was defined as the proportion of patients who achieve a PR or better. *Mantel-Haenszel estimate of the common odds ratio for unstratified tables is used. ^bP value from the Cochran-Mantel-Haenszel chi-squared test. cilta-cel, ciltacabtagene autoleucel; CR, complete response; LOT, line of therapy; MM, multiple myeloma; ORR, overall response rate; PR, partial response; SCR, stringent complete response; SCC, standard of care; VGPR, very good partial response.

Weisel, et al. ORAL P959 EHA 2024

A

219 BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

CC-95266-MM-001 (NCT04674813), a phase 1, first-in-human, multicenter, open-label, dose-finding study evaluating BMS-986393 (CC-95266), a GPRC5D-targeted autologous CAR T-cell therapy,

in pts with RRMM who had received \geq 3 prior treatment regimens and must have received a PI, a Imids, an anti-CD38 therapy, and an ASCT (if eligible); prior BCMA-directed and CAR T-cell therapies were allowed.

Escalating doses up 450×10^6 CAR T cells

Bal S et al. ASH 2023

70 patients

- 46% with high-risk cytogenetics;
- 43% extramedullary MM
- 34% penta-drug refractory;
- 43% prior BCMA-directed therapies

CRS and ICANS were mostly low-grade, with increased G \ge 3 events at the 300 and 450 \times 10⁶ CAR T-cell doses.

On-target off-tumor TRAEs, all G1/2, occurred in a minority of pts





Figure. Best overall response (A) by dose level and (B) according to prior BCMA treatment (efficacy-evaluable analysis set)^a.

Conclusions

- Real word data confirmed efficacy and manageble toxicities already shown by registrative studies.
- Hematotox and Mycare scores coud be useful for identifying suitable candidates for CAR-T in the setting of triple exposed MM.
- Ide-cel was superior to ST in pts who had received 2-4 lines of treatment, including Daratumumab (mPFS 13.3 vs 4.4 months).
- Cilta-cel was superior to ST in pts who had receive 1-3 lines, daratumumab only 20% (30 months- PFS 59% vs 25%, OS advantage).
- Initial data in patients in second-line therapy (inadequate response to ASCT, functional high-risk myeloma) are promising.




	2022	2023	2024*
Nº pazienti	9	9	25
Età mediana (range)	69 (42-77)	57 (48-77)	65 (37-78)
Indicazione • DLBCL • PMBCL • MCL • FL • LAL	5 (56%) 1 (11%) 1 (11%) 0 1 (11%)	5 (56%) 1 (11%) 3 (33%) 1 (11%) 0	14 (56%) 0 2 (8%) 6 (24%) 3 (12%)
2° linea/ >2° linea	0/9	0/9	9/16
Prodotto: • Tisa-cel • Axi-cel • Brexu-cel	5 (56%) 2 (22%) 2 (22%)	2 (22%) 5 (56%) 2 (22%)	7 (28%) 13 (52%) 5 (20%)
Δt aferesi-infusione (giorni)	42 (33-62)	42,5 (31-94)	45 (35-70)



Grazie!

Summary of incidence and management of cytopenia




Data are in n (%). CSF includes filgrastim, filgrastim AAFI, filgrastim SNDZ, granulocyte colony-stimulating factor, lenograstim, lipegfilgrastim, pegfilgrastim, pegfilgrastim BMEZ, pegfilgrastim CBQV, pegfilgrastim JMDB, and TBO filgrastim.

CD, cluster of differentiation; CSF, colony-stimulating factor; ide-cel idecabtagene vicleucel: RRC red blood cell: TPO thrombopoietin.

CSF


Summary of incidence and management of infections



Summary of incidence of SPM

	lde-cel (n = 225)		Standard regimens (n = 126)	
SPM category SPM subcategory Preferred term	All, n (%)	Incidence per 100 person- years, % (95% CI)	All, n (%)	Incidence per 100 person- years, % (95% Cl)
Any SPM	15 (7)	4 (2.4–6.7)	5 (4)	4 (1.9–10.7)
Invasive SPM	11 (5)	3 (1.6–5.3)	3 (2)	3 (1.0-8.1)
Hematologic malignancy	5 (2)	1 (0.5–3.1)	0	0
Myelodysplastic syndrome	4 (2)	-	0	-
Acute myeloid leukemia	1 (< 1)	-	0	-

CARTITUDE 4: Grade ≥3 TE infections



Presented by N Van de Donk at the 21st International Myeloma Society (IMS) Annual Meeting; September 25-28, 2024; Rio de Janeiro, Brazil

